Classification and application of metal-based nanoantioxidants in medicine and healthcare

• Nguyen Nhat Nam,
• Nguyen Khoi Song Tran,
• Tan Tai Nguyen,
• Nguyen Ngoc Trai,
• Nguyen Phuong Thuy,
• Hoang Dang Khoa Do,
• Nhu Hoa Thi Tran and
• Kieu The Loan Trinh

Beilstein J. Nanotechnol. 2024, 15, 396–415, doi:10.3762/bjnano.15.36

• : (1) nanoliposomes, which are a nanoscale bilayer lipid vesicle [132]; (2) nanocapsules, which consist of an inner aqueous core surrounded by a nontoxic polymeric membrane [133]; (3) solid lipid nanoparticles, which consist of a solid lipid core stabilized by a surfactant [134]; and (4) nanocrystals

Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• nanoparticles orally and intravenously administered has also been tested (Table 3). For example, oral solid lipid nanoparticles loaded with a poorly bioavailable lipophilic cyclic compound derived from dithiocarbazate, effectively reduced parasitemia, diminished inflammation and lesions of the liver and heart

Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review

• Douglas Dourado,
• Thayse Silva Medeiros,
• Éverton do Nascimento Alencar,
• Edijane Matos Sales and
• Fábio Rocha Formiga

Beilstein J. Nanotechnol. 2024, 15, 37–50, doi:10.3762/bjnano.15.4

• following the Ambisome® path. Nanostructured lipid carriers Nanostructured lipid carriers (NLCs) are lipid-based formulations with a solid matrix at room temperature that differ from solid lipid nanoparticles when it comes to their matrix organizational level. Nanostructured lipid carriers offer advantages

• such as enhanced stability, low toxicity, increased shelf life, improved drug loading capacity, and biocompatibility over other conventional lipid-based nanocarriers, such as nanoemulsions and solid lipid nanoparticles [91]. Due to their properties, the use of NLCs has been a successful strategy for

Nanotechnological approaches in the treatment of schistosomiasis: an overview

• Lucas Carvalho,
• Michelle Sarcinelli and
• Beatriz Patrício

Beilstein J. Nanotechnol. 2024, 15, 13–25, doi:10.3762/bjnano.15.2

• liposomes (500 mg/kg) could be more efficient than free PZQ treatment. Similar results have been shown in other works that also used liposome with PZQ in different concentrations [50][51][52][53]. In addition, Xie et al. [54] studied the pharmacokinetics of solid lipid nanoparticles composed of castor oil

• encapsulating PZQ. They observed that the drug took more than one week in vitro to be released. A pharmacokinetic study in vivo also showed that the PZQ concentration in the plasma was sustained for longer times when the nanoformulation was studied in mice. Thus, the results show that solid lipid nanoparticles

• -oxygenase used as an anti-inflammatory, analgesic, and antipyretic drug, was also effective against juvenile forms of S. mansoni when associated with solid lipid nanoparticles causing damage to parasite tegument [74]. Spironolactone is a diuretic drug mainly used to treat hypertension. Abd El Hady showed in

Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies

• Giuliana Muraca,
• María Esperanza Ruiz,
• Rocío C. Gambaro,
• Sebastián Scioli-Montoto,
• María Laura Sbaraglini,
• Gisel Padula,
• José Sebastián Cisneros,
• Cecilia Yamil Chain,
• Vera A. Álvarez,
• Cristián Huck-Iriart,
• Guillermo R. Castro,
• María Belén Piñero,
• Matias Ildebrando Marchetto,
• Catalina Alba Soto,
• Germán A. Islan and
• Alan Talevi

Beilstein J. Nanotechnol. 2023, 14, 804–818, doi:10.3762/bjnano.14.66

• efficiently. Many developments have been made in the past years resulting in lipid formulations such as liposomes, solid lipid nanoparticles (SLNs), and nanoemulsions, which increased the apparent solubility of BNZ and its efficacy against parasites [17]. Remarkably, oil-in-water nanoemulsions improved the

Use of nanosystems to improve the anticancer effects of curcumin

• Andrea M. Araya-Sibaja,
• Norma J. Salazar-López,
• Krissia Wilhelm Romero,
• José R. Vega-Baudrit,
• J. Abraham Domínguez-Avila,
• Carlos A. Velázquez Contreras,
• Ramón E. Robles-Zepeda,
• Mirtha Navarro-Hoyos and
• Gustavo A. González-Aguilar

Beilstein J. Nanotechnol. 2021, 12, 1047–1062, doi:10.3762/bjnano.12.78

• treatments, which was accompanied by a dose-dependent increase in cytochrome C expression and a dose-dependent decrease in CDK1 expression. Solid lipid nanoparticles (SLN). SLN were first developed ca. 1990 (with patents and papers published a few years after) [60] and are the first generation of lipid

Photothermally active nanoparticles as a promising tool for eliminating bacteria and biofilms

• Mykola Borzenkov,
• Piersandro Pallavicini,
• Angelo Taglietti,
• Laura D’Alfonso,
• Maddalena Collini and
• Giuseppe Chirico

Beilstein J. Nanotechnol. 2020, 11, 1134–1146, doi:10.3762/bjnano.11.98

• studied. The state-of-the art in antimicrobial polymeric nanoparticles, with an emphasis on the relationship between their structure and activity, is well presented in a recent review [29]. The antibacterial properties of solid lipid nanoparticles are also a subject of specific research interest as they

Key for crossing the BBB with nanoparticles: the rational design

• Sonia M. Lombardo,
• Marc Schneider,
• Akif E. Türeli and
• Nazende Günday Türeli

Beilstein J. Nanotechnol. 2020, 11, 866–883, doi:10.3762/bjnano.11.72

• nanoparticles (AuNPs); blood–brain barrier (BBB); drug delivery; liposomes; nanomedicine; polymeric nanoparticles; solid lipid nanoparticles; superparamagnetic iron oxide nanoparticles (SPIONs); Introduction Neurological disorders and brain diseases are real burdens for modern societies and healthcare systems

• the survival time of mice when loaded with paclitaxel. Thus, this formulation could be a promising drug delivery system for antitumor therapy. Solid lipid nanoparticles: Solid lipid nanoparticles (SLNs) are particles with a solid lipid core at room and body temperature [27]. SLNs can be prepared with

Frontiers in pharmaceutical nanotechnology

• Matthias G. Wacker

Beilstein J. Nanotechnol. 2019, 10, 2538–2540, doi:10.3762/bjnano.10.244

• announced the approval of a first-of-its-kind RNA interference (RNAi)-based drug, Onpattro™, which uses solid lipid nanoparticles to protect the sensitive compound from early degradation. Again, lipid materials rather than synthetic polymers have been used for drug delivery applications. In pharmaceutical

BergaCare SmartLipids: commercial lipophilic active concentrates for improved performance of dermal products

• Florence Olechowski,
• Rainer H. Müller and
• Sung Min Pyo

Beilstein J. Nanotechnol. 2019, 10, 2152–2162, doi:10.3762/bjnano.10.208

• inclusion; nanostructured lipid carriers (NLCs); penetration enhancement; skin occlusion; SmartLipids; solid lipid nanoparticles (SLNs); Introduction To meet the increasing expectations and demands of consumers in personal care and cosmetics, as well of patients in medical care, dermal delivery systems are

• , ethosomes, transfersomes, pharmacosomes, herbosomes, colloidosomes, sphinosomes and cubosomes [3]. A step forward in 1991 was the development of a carrier made from solid lipids, the solid lipid nanoparticles (SLNs). They are derived from the emulsions by replacing the liquid lipid (oil) with a solid lipid

• with solid lipid nanoparticles (Figure 10, lower row) [36] The distinctly reduced side effects of tretinoin released from lipid nanoparticles can be explained by a controlled release, avoiding high peak concentrations of free tretinoin on the skin. In dermal sunscreen formulations, the lipophilic

Microfluidic manufacturing of different niosomes nanoparticles for curcumin encapsulation: Physical characteristics, encapsulation efficacy, and drug release

• Mohammad A. Obeid,
• Ibrahim Khadra,
• Abdullah Albaloushi,
• Margaret Mullin,
• Hanin Alyamani and
• Valerie A. Ferro

Beilstein J. Nanotechnol. 2019, 10, 1826–1832, doi:10.3762/bjnano.10.177

• unwanted side effects [8][9]. Liposomes, solid lipid nanoparticles, dendrimers, micelles, polymeric nanoparticles, gold nanoparticles, and carbon nanotubes are among the most common types of nanoparticle delivery systems [10]. These efforts have been reported in several studies. For example, Guo et al

Lipid nanostructures for antioxidant delivery: a comparative preformulation study

• Elisabetta Esposito,
• Maddalena Sguizzato,
• Markus Drechsler,
• Paolo Mariani,
• Federica Carducci,
• Claudio Nastruzzi,
• Giuseppe Valacchi and
• Rita Cortesi

Beilstein J. Nanotechnol. 2019, 10, 1789–1801, doi:10.3762/bjnano.10.174

• against pollutants. Namely, solid lipid nanoparticles and nanostructured lipid carriers were prepared using different lipids (tristearin, compritol, precirol or suppocire) in the presence or absence of caprylic/capric triglycerides. The formulations were characterized by particle size analysis, cryogenic

• solid lipid nanoparticles, suggesting their suitability for antioxidant loading. Based on the preformulation study, tristearin-based nanostructured lipid carriers loaded with α-tocopherol were selected for ex vivo studies since they displayed superior physico-chemical properties as compared to the other

• lipid carriers (NLCs); retinoic acid; skin pollution; solid lipid nanoparticles (SLNs); Introduction Air pollution increasingly affects industrialized urban areas in a negative manner with dramatic consequences for the environment and human health. This problem also affects rural areas, worsening the

Nanoporous smartPearls for dermal application – Identification of optimal silica types and a scalable production process as prerequisites for marketed products

• David Hespeler,
• Sanaa El Nomeiri,
• Jonas Kaltenbach and
• Rainer H. Müller

Beilstein J. Nanotechnol. 2019, 10, 1666–1678, doi:10.3762/bjnano.10.162

• solution, because the application of simple suspensions to the skin normally does not provide a sufficient dermal bioavailability. Classic delivery systems such as liposomes [3] or solid lipid nanoparticles (SLNs) [4][5] do not work because the active agents do not dissolve in the lipidic phase of these

Nanoscale isoindigo-carriers: self-assembly and tunable properties

• Tatiana N. Pashirova,
• Andrei V. Bogdanov,
• Lenar I. Musin,
• Julia K. Voronina,
• Irek R. Nizameev,
• Marsil K. Kadirov,
• Vladimir F. Mironov,
• Lucia Ya. Zakharova,
• Shamil K. Latypov and
• Oleg G. Sinyashin

Beilstein J. Nanotechnol. 2017, 8, 313–324, doi:10.3762/bjnano.8.34

• and hydrogen bonding. Another strategy is the use of soft matter (micelles, emulsions, dendrimers, nanospheres, solid lipid nanoparticles or liposomes) as the delivery vehicle. These studies have been encouraged by the possibility to prevent side effects, to increase drug bioavailability, to decrease